Drug reference

colloidal bismuth subcitrate

Ulcer protective, Anti-H. pylori drug · Drugs for peptic ulcer, Anti-H. pylori

Ulcer protective, Anti-H. pylori drugDrugs for peptic ulcer, Anti-H. pylori

CDSCO approved

EXCRETION

—

not curated

INTERACTIONS

—

none in our sources

PREGNANCY

—

not curated

Mechanism

The mechanism of action is not entirely clear but probabilities include increasing gastric mucosal PGE2, mucus, and HCO3̄ production. It may precipitate mucus glycoproteins to coat the ulcer base and directly detach and inhibit H. pylori.

Indications

Ulcer healingGastritis associated with H. pyloriNonulcer dyspepsia associated with H. pyloriComponent of triple drug anti-H. pylori regimenQuadruple drug anti-H. pylori regimen (for eradication failure)

Dosing

Adult: 120 mg (as Bi2O3) taken ½ hr before 3 major meals and at bedtime for 4–8 weeks. Milk and antacids should not be taken concomitantly. For quadruple therapy: 120 mg QID.